Shionogi Stays The Course As It Lays Out R&D Priorities
Japan's Shionogi lays out its R&D priorities, with a continued strategic focus on anti-infectives and CNS drugs, saying it is looking for the approval of four molecules in the coming year.
You may also be interested in...
Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.
Major private equity group Blackstone buys into pharma for its first acquisition in Japan, but amid challenges in the sector, the attractions take some unraveling.
Japanese firm in discussions with regulator as high-need novel therapy for spinocerebellar degeneration misses endpoint but shows promise in pooled analysis.